BACKGROUND The use of drug-eluting stents (DES) in patients at high risk of bleeding or thrombosis has not been
C ompared with bare metal stents (BMS), drug-eluting stents (DES) have consistently been shown to reduce restenosis rates, and consequently, the risk of target vessel failure (1) (2) (3) (4) . However, due to a higher incidence of very late stent thrombosis, first-generation DES raised safety concerns (5) (6) (7) . Therefore, to restore safety to a level comparable to that after BMS implantation, a prolonged course of dual-antiplatelet therapy (DAPT) has been recommended after DES implantation (8, 9) .
Consequently, the use of DES instead of BMS remains controversial in selected patient and/or lesion subsets, including patients at high thrombosis risk, who may have a higher risk for coronary events after DES implantation, and those at high bleeding risk, in whom long-term DAPT poses safety concerns (9, 10) . Similarly, patients at a low perceived risk for in-stent restenosis may not qualify as good DES candidates, because the need for prolonged DAPT and the long-term risk for adverse events after DES implantation may outweigh the acknowledged benefit of lower reintervention rates.
The zotarolimus-eluting stent (ZES) is a hydrophilic polymer-based, second-generation device with a uniquely fast drug-release profile (11) . The phosphorylcholine coating has been shown to reduce thrombus formation on the coated stent struts compared with BMS (12) . Although the rapid-release profile may result in less powerful inhibition of intimal hyperplasia, it may also lead to a more rapid and/or complete stent strut coverage compared with other DES (4, 13, 14) , raising the possibility that it might be feasible to shorten DAPT duration while maintaining superior efficacy compared with BMS (15) . This could be evaluated further in dedicated studies.
The purpose of this trial was to assess if ZES implantation, followed by a shorter than the currently recommended course of DAPT, on the basis of the patient's clinical profile (tailored DAPT) and independent of stent type, would decrease the incidence of 12-month major adverse cardiovascular events (MACE) in uncertain DES recipients, including those with high bleeding or thrombotic risk and those with low restenosis risk, compared with BMS.
METHODS
STUDY DESIGN AND POPULATION. The ZEUS (Zotarolimus-eluting Endeavor sprint stent in Uncertain DES candidates) trial is a multinational, randomized, single-blinded trial, conducted at 20 sites in 4 European countries (Italy, Switzerland, Portugal, and Hungary). It was designed to evaluate the combined efficacy and safety of ZES compared with BMS, in uncertain DES candidates (16) . Detailed inclusion and exclusion criteria have been previously described (16) and are detailed in the Online Appendix. In brief, patients who underwent elective, urgent, or emergent percutaneous coronary intervention with intended stent implantation were randomly assigned in a 1:1 fashion to ZES or a thin-strut (thickness <100 mm) BMS, if they were ages 18 years or older and had at least 1 qualifying criterion among the pre-specified uncertain DES recipients. High-bleeding risk status was defined as the following: a clinical indication for treatment with oral anticoagulant agents; recent bleeding episode(s) that required medical attention; previous bleeding episode(s) that required hospitalization if the bleeding diathesis has not been completely resolved (that is, surgical removal of the bleeding source); age older than 80 years; systemic conditions associated with increased bleeding risk (e.g., hematological disorders or any known coagulopathy-determining bleeding diathesis, including history of or current thrombocytopenia, which was defined as platelet count <100,000/mm Valgimigli et al.
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CHARACTERIZATION OF THE INCLUDED PATIENT
POPULATION. Figure 1A shows the distribution of the inclusion criteria in the recruited patient population.
Approximately one-half of the patients (n ¼ 828) patients. Figure 1B shows the cumulative frequency of DAPT duration from randomization to the first planned permanent discontinuation in the 2 study groups. Values are mean AE SD or n (%), unless otherwise indicated. *There were no significant between-group differences. †Calculated in 802 patients in the BMS arm and in 800 patients in the ZES arm; ACC/AHA scores were missing in 6 patients. ‡As described in Ellis et al. (30) , type A stenoses were coded 1 point; type B1 stenoses, 2 points; type B2 stenoses, 3 points; and type C stenoses, 4 points.
ACC/AHA ¼ American College of Cardiology/American Heart Association; ACE ¼ angiotensin-converting enzyme; CFX ¼ circumflex artery; LAD ¼ left anterior descending artery; LMCA ¼ left main coronary artery; RCA ¼ right coronary artery; SVG ¼ saphenous vein graft; other abbreviations as in Table 1 . Bleeding endpoints, reported in Table 3 , did not differ between groups.
SUBGROUP ANALYSIS. As shown in Figure 2 , when outcomes in terms of the primary endpoint of death from any cause, MI, or TVR, as well as for the secondary endpoint of death from any cause or MI were separately appraised across patients at high risk of bleeding or thrombosis or at low risk of restenosis, there was no signal of heterogeneity.
DISCUSSION
The ZEUS study focused on a unique patient population that was largely excluded from the pivotal DES trials that led to regulatory approval. We studied patients with high bleeding risk, high thrombotic risk, or low restenosis risk. Furthermore, the duration of antiplatelet therapy specified in the protocol was based not on the type of stent implanted (DES vs. BMS), but on the patient's perceived risk profile.
The advent of DES led to the recommendation that a more prolonged course of DAPT be mandated, compared with the shorter duration recommended for BMS (1, 19) . Hence, the effect of DES implantation has never been disentangled from that offered by a prolonged DAPT regimen. The ZES is a unique second-generation device, in that it is completely hydrophilic polymer-based, and has a specific fast-release drug profile. Although the rapid-release profile (<2 weeks) results in less powerful inhibition of intimal hyperplasia (4) , it leads to more rapid and complete stent strut coverage compared with other DES, suggesting that it might be feasible to shorten DAPT duration while maintaining superior efficacy compared with BMS (11, 15, 26) .
The thrombogenicity of BMS has long been recognized (27) .
The polymer coating in the ZES is hydrophilic and highly biocompatible, and potentially serves as a barrier to diminish the thrombogenic potential of the metal stent struts (11) . Multiple studies comparing new-generation DES versus BMS have observed a lower stent thrombosis and/or target vessel-related MI risk after DES (5, 28, 29) . The interplay between the lower thrombogenicity of the device and the ability to reduce late loss-related coronary events has been formulated as a putative explanation for these findings. However, all these studies have systematically mandated a prolonged (and frequently much longer) DAPT regimen for DES patients compared with BMS patients (4, 28, 29) . Hence, these studies (unlike ours) failed to disentangle the effects of the device from those of the concomitant antiplatelet therapy. Further research is needed to ascertain if the tailored DAPT regimen tested in our study can be safely implemented in patients who receive other 
BMS Better E-ZES Better
No. of patients HAZARD RATIO (95% CI)
P-VALUES Interaction
Subgroup analyses for the 3 major inclusion criteria for which randomization was stratified are shown, with HRs and 95% CIs for the primary endpoint of death from any cause, MI, or TVR, as well as for the secondary endpoint of death for any cause or MI in 1,606 patients randomly assigned to either ZES or BMS. The p value for interaction represents the likelihood of interaction between the variable and the relative treatment effect. CI ¼ confidence interval; HR ¼ hazard ratio; MI ¼ myocardial infarction; TVR ¼ target vessel revascularization; other abbreviations as in Figure 1 . Zotarolimus Stent in Uncertain DES Candidates DES. Longer follow-up is needed to assess the durability of our study results over time.
CONCLUSIONS
The ZEUS study showed that a treatment strategy consisting of ZES implantation followed by a per- 
